Buying The Most Time: CareDx’s Diagnostics For Transplant Recipients
Executive Summary
An organ transplant is not a “one and done” procedure, and patients require lifelong post-operative monitoring. Medtech Insight spoke to CareDx about how monitoring could improve patient outcomes.
You may also be interested in...
Minute Insight: CareDx Enters Donor Organ Procurement Market With MediGO Acquisition
MediGo extends CareDX’s digital product lineup while expanding its reach into the organ procurement organization market.
Coverage Decisions For AlloMap Molecular Testing To Detect Cardiac Allograft Rejections Left Up To MACs
The US CMS has proposed that due to low Medicare use, it will not nationally cover AlloMap molecular tests to detect cardiac allograft rejections.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.